Table 1.
Selected phase II/III/IV clinical trials of immune checkpoint inhibitor combinations in various human cancers. Data source ClinicalTrials.gov (www.clinicaltrials.gov, accessed on 25 June 2022).
| Disease Condition | Drug Combination | Phase | Participants | Status | NCT Number |
|---|---|---|---|---|---|
| Non-small cell lung cancer |
Durvalumab (anti-PDL1), Oleclumab (anti-CD73), Monalizumab (anti-NKG2A) Durvalumab (anti-PDL1), Domvanalimab (anti-TIGIT) Atezolizumab (anti-PDL1), Pemetrexed, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel |
III III III |
999 860 114 |
Recruiting Recruiting Recruiting |
NCT05221840 NCT05211895 NCT05047250 |
| Extensive stage small cell lung cancer | Atezolizumab (anti-PDL1), Chemotherapy (Carboplatin-etoposide) |
III |
200 |
Not yet recruiting |
NCT05468489 |
| Metastatic non-small cell lung cancer | Pembrolizumab (anti-PD1), Datopotamab deruxtecan (ADC with TROP2 Ab and Dato-DXd, DS-1062a) Ipilimumab (anti-CTLA-4), Nivolumab (anti-PD1) |
III III |
740 265 |
Recruiting Active, not recruiting |
NCT05215340 NCT03469960 |
| Squamous cell non-small cell lung cancer | Sintilimab (anti-PD1), Carboplatin, Albumin-Bound Paclitaxel | III | 236 | Not yet recruiting | NCT05429463 |
| Head and Neck squamous cell carcinoma | Monalizumab (anti-NKG2A), Cetuximab (anti-EGFR) |
III | 624 | Recruiting | NCT04590963 |
| Nasopharyngeal carcinoma |
PD-1 antibody, Capecitabine | III | 556 | Recruiting | NCT05342792 |
| Gastric cancer | SHR-1701 (bifunctional antibody against PD-L1 and TGF-βRII) | III | 896 | Enrolling by invitation | NCT05149807 |
| Colorectal carcinoma | Sintilimab (anti-PD1), Oxaliplatin, Capecitabine | III | 323 | Recruiting | NCT05236972 |
| Anal cancer | Sintilimab (anti- PD-1), Chemoradiotherapy | III | 102 | Recruiting | NCT05374252 |
| Metastatic urothelial cancer |
Avelumab (anti-PDL1), Cabozantinib S-malate | III | 654 | Recruiting | NCT05092958 |
| Renal cell carcinoma | Nivolumab (anti-PD1), Tivozanib | III | 326 | Recruiting | NCT04987203 |
| Acute myeloid leukemia | Magrolimab (anti-CD47), Venetoclax, Azacitidine | III | 432 | Recruiting | NCT05079230 |
| Relapsed or refractory myeloma |
Talquetamab (bispecific Ab binding CD3 and GPRC5D), Daratumumab (anti-CD38), Pomalidomide, Dexamethasone | III | 810 | Not yet Recruiting | NCT05455320 |
| Recurrent myeloma | Satuximab (anti-CD38), Dexamethasone, Pomalidomide | III | 534 | Recruiting | NCT05405166 |
| Melanoma | Fianlimab (anti-LAG3), Cemiplimab (anti-PD1), Pembrolizumab (anti-PD1) Nivolumab (anti-PD1) (subcutaneously versus intravenous), rHuPH20 |
III III |
1100 286 |
Recruiting Recruiting |
NCT05352672 NCT05297565 |
| Breast cancer | Inetetamab (anti-HER2), Toripalimab (anti-PD1), Albumin-Bound Paclitaxel | IV | 70 | Not yet Recruiting | NCT05291910 |